Clinical Trial Update: Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tesetaxel as second-line therapy for advanced gastric cancer, including gastric and gastroesophageal junction adenocarcinomas.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• tesetaxel (tesetaxel)

Snippet

Sponsor: Genta Incorporated | Conditions: Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction | Phase 2 | Status: UNKNOWN